<DOC>
	<DOCNO>NCT00190242</DOCNO>
	<brief_summary>Immunogenicity reduce immunocompromised patient . The aim prospective randomize study evaluate tolerance immunogenicity 2 dos versus 3 dos anti-HAV vaccine HIV-1 infect patient CD4 count 200 500 per mm3 , co-infected HBV and/or HCV . The factor influence vaccine immunogenicity evaluate .</brief_summary>
	<brief_title>Immunogenicity Tolerance Two Strategies Anti-HAV Vaccination HIV-infected Patients</brief_title>
	<detailed_description>RECOMMANDATIONS hepatitis A vaccination HIV-infected patient general population . However , immunogenicity induce 2 dos anti-HAV vaccine lower HIV-infected patient . The primary objective study compare immunogenicity ( percentage patient anti-HAV antibody &gt; 20 mUI/ml month 7 ) 2 strategy ( 2 dos month 1 6 , versus 3 dos month 1 , 2 6 ) anti-HAV vaccine HIV-1 infect patient co-infected HBV and/or HCV CD4 cell count 200 500/mm3 . The second objective compare mean anti-HAV antibody titer obtain 2 strategy , durability seroprotection 12 month end vaccination , safety . The PARAMATERS may effect immune response evaluate . This open , prospective , study include 99 patient , age 18 55 year old . Patients randomize receive 2 3 dos HAVRIX 1440 UI intramuscularly week O , 4 , 24 week 0 , 24 . Clinical biological safety evaluate immunisation blood sample serological evaluation take week -4 , 4 , 8 , 24 28 immunogenicity week 72 long term analysis</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>VIH1 infection , age 1855 year negative antiHAV IgG CD4 cell count 200 500/mm3 prior antiHAV vaccination immunosuppressive treatment splenectomy Prothrombin time &lt; 50 % , platelet &lt; 50 000/mm3 fever serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) activity &gt; 2 ULN non coinfected patient , &gt; 5 ULN coinfected patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>HIV</keyword>
	<keyword>hepatitis A</keyword>
	<keyword>vaccine</keyword>
	<keyword>HBV and/or HCV co-infection</keyword>
</DOC>